Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1925-1934

  Liu, Xiaoxia ^a   Cao, Lingling ^b   Ni, Jinsong ^a   Liu, Ning ^a   Zhao, Xiaoming ^b   Wang, Yanfang ^a   Zhu, Lin ^b   Wang, Lingyao ^b   Wang, Jin ^a   Yue, Ying ^a   Cai, Yong ^b   Jin, Jingji ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

BCCIP gene; Colorectal cancer; Ovarian cancer; Renal cell carcinoma

Indexed keywords

PROTEIN; PROTEIN BCCIP; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BCCIP GENE; CANCER GRADING; CANCER STAGING; CANCER TISSUE; COLLOID CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVARY CANCER; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; BRCA2 PROTEIN; CALCIUM-BINDING PROTEINS; CARCINOMA, RENAL CELL; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTEIN ISOFORMS; RNA, MESSENGER;

EID: 84891922223     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2124     Document Type: Article

References (30)

1. Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase. J Biol Chem 275: 31145-31154, 2000.
2. Liu J, Yuan Y, Huan J and Shen Z: Inhibition of breast and brain cancer cell growth by BCCIPá, an evolutionarily conserved nuclear protein that interacts with BRCA2. Oncogene 20: 336-345, 2001.
3. Meng X, Liu J and Shen Z: Genomic structure of the human BCCIP gene and its expression in cancer. Gene 302: 139-146, 2003.
4. Fan J, Wray J, Meng X and Shen Z: BCCIP is required for the nuclear localization of the p21 protein. Cell Cycle 8: 3019-3024, 2009.
5. Lu H, Guo X, Meng X, Liu J, Allen C, Wray J, Nickoloff JA and Shen Z: The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol Cell Biol 25: 1949-1957, 2005.
6. Meng X, Liu J and Shen Z: Inhibition of G1 to S cell cycle progression by BCCIPβ. Cell Cycle 3: 343-348, 2004.
7. Waf1/Cip1. Cell Cycle 3: 1457-1462, 2004.
8. Meng X, Fan J and Shen Z: Roles of BCCIP in chromosome stability and cytokinesis. Oncogene 26: 6253-6260, 2007.
9. Wray J, Liu J, Nickoloff JA and Shen Z: Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication stress. Cancer Res 68: 2699-2707, 2008.
10. Lu H, Huang YY, Mehrotra S, Droz-Rosario R, Liu J, Bhaumik M, White E and Shen Z: Essential roles of BCCIP in mouse embryonic development and structural stability of chromosomes. PLoS Genet 7: e1002291, 2011.
11. Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin 62: 10-29, 2012.
12. Jemal A, Siegel E, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
13. Sameer AS: Colorectal cancer: molecular mutations and polymorphisms. Front Oncol 3: 114, 2013.
14. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smish KD, Cushing RC and Seagroves TN: Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14: R6, 2012.
15. McDonald PC, Winum JY, Supuran CT and Dedhar S: Recent developments in targeting carbonate anhydrase IX for cancer therapeutics. Oncotarget 3: 84-97, 2012.
16. Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res 316: 466-476, 2010.
17. Choschzick M, Oosterwijk E, Müller V, Woelber L, Simon R, Moch H and Tennstedt P: Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 459: 193-200, 2011.
18. Seeber LM, Horrée N, Vooijs MA, Heintz AP, van der Wall E, Verheijen RH and van Diest PJ: The role of hypoxia inducible factor-1 alpha in gynecological cancer. Crit Rev Oncol Hematol 78: 173-184, 2011.
19. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer, Chicago, IL, 2010.
20. Tavassoli FA and Devilee P (eds): Patholology and genetics. Tumors of the breast and female genital organs. In: World Health Organization Classification of Tumors. IARC Press, Lyon, 2003.
21. Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Morravan V and Swenerton K: Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39: 1239-1251, 2008.
22. Mostofi FK (ed): Histological typing of kidney tumors. In: World Health Organization International Classification of Tumors. Springer-Verlag, New York, NY, 1998.
23. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
24. Merlo A: Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev 26: 145-158, 2003.
25. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM and Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
26. Powell SN and Kachnic LA: Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 22: 5784-5791, 2003.
27. Daniels MJ, Wang Y, Lee M and Venkitaraman AR: Abnormal cytokinesis in cells deficient in the breast cancer susceptibility BRCA2. Science 306: 876-879, 2004.
28. Rudkin TM and Foulkes WD: BRCA2: breaks, mistakes and failed separations. Trends Mol Med 11: 145-148, 2005.
29. Lu H, Yue J, Meng X, Nickoloff JA and Shen Z: BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage. Necleic Acids Res 35: 7160-7170, 2007.
30. Liu J, Lu H, Ohgaki H, Merlo A and Shen Z: Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer 9: 268, 2009.